Crinetics Pharmaceuticals (CRNX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Key Insights
Critical company metrics and information
Share Price
$58.87Market Cap
$5.46 BillionTotal Outstanding Shares
92.74 Million SharesTotal Employees
210Dividend
No dividendIPO Date
July 18, 2018SIC Description
Pharmaceutical PreparationsHomepage
https://www.crinetics.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $174.47 Million |
Net Cash Flow From Financing Activities, Continuing | $494.32 Million |
Net Cash Flow From Investing Activities, Continuing | $-120.04 Million |
Net Cash Flow From Investing Activities | $-120.04 Million |
Net Cash Flow From Financing Activities | $494.32 Million |
Net Cash Flow | $174.47 Million |
Net Cash Flow From Operating Activities, Continuing | $-199.81 Million |
Net Cash Flow From Operating Activities | $-199.81 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Revenues | $1.04 Million |
Benefits Costs and Expenses | $218.54 Million |
Costs And Expenses | $299.73 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Diluted Earnings Per Share | $3.71 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Nonoperating Income/Loss | $33.53 Million |
Income/Loss From Continuing Operations Before Tax | $-217.50 Million |
Basic Average Shares | $234.46 Million |
Operating Expenses | $307.81 Million |
Income/Loss From Continuing Operations After Tax | $-277.91 Million |
Other Operating Expenses | $86.38 Million |
Diluted Average Shares | $234.46 Million |
Net Income/Loss Attributable To Parent | $-277.91 Million |
Depreciation and Amortization | $2.26 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Research and Development | $219.17 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-277.91 Million |
Net Income/Loss | $-277.91 Million |
Basic Earnings Per Share | $3.71 |
Operating Income/Loss | $-306.77 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Equity | $832.98 Million |
Cash | $862.70 Million |
Assets | $937.37 Million |
Liabilities And Equity | $937.37 Million |
Other Non-current Assets | $48.08 Million |
Liabilities | $104.39 Million |
Noncurrent Liabilities | $50.83 Million |
Noncurrent Assets | $59.79 Million |
Accounts Payable | $4.94 Million |
Other Current Assets | $14.89 Million |
Other Current Liabilities | $48.62 Million |
Current Liabilities | $53.56 Million |
Equity Attributable To Parent | $832.98 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Current Assets | $877.59 Million |
Fixed Assets | $11.71 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.